Floatz logo

2,4,6-OCTATRIENOIC ACID, 8-(3,4-DIHYDRO-1(2H)-NAPHTHALENYLIDENE)-3,7-DIMETHYL-, (2E,4E,6Z,8E)-

Anatomic Stage I Breast Cancer AJCC v8

National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

891 Active assets in the Anatomic Stage I Breast Cancer AJCC v8 cohort.

Asset / SponsorPhaseRating
Lapatinib
University of New Mexico
Phase 3BBB
Darolutamide
Vandana Abramson
Phase 2BBB
Trastuzumab Duocarmazine
Byondis B.V.
Phase 3BB
ERIBULIN MONOMETHANESULFONATE
Henan Cancer Hospital
Phase 4BB
Palbociclib
Hoffmann-La Roche
Phase 4BB

View all 50 →

Same molecule, other indications

2,4,6-OCTATRIENOIC ACID, 8-(3,4-DIHYDRO-1(2H)-NAPHTHALENYLIDENE)-3,7-DIMETHYL-, (2E,4E,6Z,8E)- is also rated in:

skin carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
breast carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
ductal breast carcinoma in situDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →